NEW ORLEANS, LA — Research led by Lauren Cole, a public health graduate student, and Dr. Edward Peters, Associate Professor of Public Health and Director of the Epidemiology Program at LSU Health Sciences Center New Orleans, reports that the incidence of head and neck cancer has risen at sites associated with Human Papilloma Virus (HPV) infection, with the greatest increase among middle-aged white men. At the same time, younger, Non-Hispanic blacks experienced a substantial decrease in these cancers.
They also found that the disease process for tumors associated with HPV is different from those caused by exposure to tobacco and alcohol, with implications for treatment. The findings are published this month in the PLoS ONE journal.
Tobacco and alcohol are the most common risk factors for cancers of the head and neck, but HPV infection is emerging as an important risk factor as well. The objectives of this study were to assess the recent incidence of head and neck cancer in the United States and to investigate the trends of these cancers associated with HPV infection.
Using incidence data for 1995-2005 from 40 US population-based cancer registries, the researchers described the epidemiology of head and neck cancer (HNC) in the US and examined the variation in cancer rates by age, sex, race/ethnicity, stage and cancer location. As some HNC sites are strongly associated with a tendency for HPV infection, they also examined if rates varied by those sites associated with HPV.
“During 1995-2005, we observed a significant overall increase in head and neck cancer incidence among HPV-associated sites, while in the same time period, non HPV-associated sites underwent a significant decline in incidence,” notes Lauren Cole, an Epidemiology PhD student at LSU Health Sciences Center New Orleans School of Public Health.
The researchers found overall, younger age groups, Non-Hispanic Whites and Hispanics experienced greater increases in incidence for HPV-associated sites, while incidence declined for Non-Hispanic Blacks independent of HPV-association of site. The evidence from this large population-based study suggests that since the disease process for HPV-associated tumors is different, HPV tumor status should be incorporated into treatment decisions for head and neck cancer patients to improve prognosis and survival.
“With the introduction of the HPV vaccine, this study suggests that the vaccine can not only be used to help prevent cervical cancer, but head and neck cancer as well,” adds Dr. Edward Peters, Associate Professor and Director of the Epidemiology Program at the LSU Health Sciences Center New Orleans School of Public Health.
Head and neck cancer includes cancer in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx (voice box). According to the National Cancer Institute, head and neck cancers account for approximately 3 percent of all cancers in the United States. These cancers are nearly twice as common among men as they are among women.
Head and neck cancers are also diagnosed more often among people over age 50 than they are among younger people. More than 52,000 men and women in this country were expected to be diagnosed with head and neck cancers last year.
This research was supported by the North American Association of Central Cancer Registries (NAACCR) and the Louisiana Tumor Registry at LSU Health Sciences Center New Orleans School of Public Health.